Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The group expects to raise nearly $170m.
Can the company add a Car-T string to its stem cell transplant bow?
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
